Cargando…
Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells
BACKGROUND: Farnesyltransferase inhibitor tipifarnib (R115777) has been used for treatment of hematological malignancies; however, its observed anticancer effect was limited. This prompted us to search for inhibitors that would show synergic, proapoptotic effect when combined with R115777. We decide...
Autores principales: | Krzykowska-Petitjean, Katarzyna, Małecki, Jędrzej, Bentke, Anna, Ostrowska, Barbara, Laidler, Piotr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278622/ https://www.ncbi.nlm.nih.gov/pubmed/22209975 http://dx.doi.org/10.1007/s00432-011-1131-9 |
Ejemplares similares
-
Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007) -
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008) -
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension
por: Duluc, Lucie, et al.
Publicado: (2017) -
Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis
por: Katragadda, Usha, et al.
Publicado: (2013) -
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)